JP2023526418A - 非アルコール性脂肪性肝炎（ｎａｓｈ）の処置 - Google Patents

非アルコール性脂肪性肝炎（ｎａｓｈ）の処置 Download PDF

Info

Publication number
JP2023526418A
JP2023526418A JP2022570478A JP2022570478A JP2023526418A JP 2023526418 A JP2023526418 A JP 2023526418A JP 2022570478 A JP2022570478 A JP 2022570478A JP 2022570478 A JP2022570478 A JP 2022570478A JP 2023526418 A JP2023526418 A JP 2023526418A
Authority
JP
Japan
Prior art keywords
25hc3s
salt
subject
nash
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022570478A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021237146A5 (enExample
Inventor
リン，ウェイチー
イー． ブラウン，ジェームス
Original Assignee
デュレクト コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デュレクト コーポレーション filed Critical デュレクト コーポレーション
Publication of JP2023526418A publication Critical patent/JP2023526418A/ja
Publication of JPWO2021237146A5 publication Critical patent/JPWO2021237146A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
JP2022570478A 2020-05-22 2021-05-21 非アルコール性脂肪性肝炎（ｎａｓｈ）の処置 Pending JP2023526418A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063029364P 2020-05-22 2020-05-22
US63/029,364 2020-05-22
US202063030213P 2020-05-26 2020-05-26
US63/030,213 2020-05-26
US202063113119P 2020-11-12 2020-11-12
US63/113,119 2020-11-12
US202163146556P 2021-02-05 2021-02-05
US63/146,556 2021-02-05
PCT/US2021/033746 WO2021237146A1 (en) 2020-05-22 2021-05-21 Treatment of non-alcoholic steatohepatitis (nash)

Publications (2)

Publication Number Publication Date
JP2023526418A true JP2023526418A (ja) 2023-06-21
JPWO2021237146A5 JPWO2021237146A5 (enExample) 2024-05-28

Family

ID=78707648

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022570478A Pending JP2023526418A (ja) 2020-05-22 2021-05-21 非アルコール性脂肪性肝炎（ｎａｓｈ）の処置

Country Status (11)

Country Link
US (1) US20230181602A1 (enExample)
EP (1) EP4153165A4 (enExample)
JP (1) JP2023526418A (enExample)
KR (1) KR20230015940A (enExample)
CN (1) CN115803061A (enExample)
AU (1) AU2021273937A1 (enExample)
BR (1) BR112022023128A2 (enExample)
CA (1) CA3183119A1 (enExample)
MX (1) MX2022014574A (enExample)
TW (1) TW202210082A (enExample)
WO (1) WO2021237146A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018026781A1 (en) 2016-08-02 2018-02-08 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016510720A (ja) * 2013-03-15 2016-04-11 持田製薬株式会社 非アルコール性脂肪性肝炎治療のための組成物および方法
WO2018193006A1 (en) * 2017-04-18 2018-10-25 Genfit Combination of elafibranor or derivatives thereof with an anti-nash, anti-fibrotic or anti-cholestatic agent
WO2019071216A1 (en) * 2017-10-06 2019-04-11 Gilead Sciences, Inc. POLYTHERAPY COMPRISING AN ACC INHIBITOR
JP2019526542A (ja) * 2016-08-02 2019-09-19 デュレクト コーポレーション 酸素化コレステロールサルフェート、並びにポリアルキレングリコール、カルボキシメチルセルロース、及びポリオキシルグリセリドのうち少なくとも１種を含む組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047022A1 (en) * 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US8399441B2 (en) * 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
US9034859B2 (en) * 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016510720A (ja) * 2013-03-15 2016-04-11 持田製薬株式会社 非アルコール性脂肪性肝炎治療のための組成物および方法
JP2019526542A (ja) * 2016-08-02 2019-09-19 デュレクト コーポレーション 酸素化コレステロールサルフェート、並びにポリアルキレングリコール、カルボキシメチルセルロース、及びポリオキシルグリセリドのうち少なくとも１種を含む組成物
WO2018193006A1 (en) * 2017-04-18 2018-10-25 Genfit Combination of elafibranor or derivatives thereof with an anti-nash, anti-fibrotic or anti-cholestatic agent
WO2019071216A1 (en) * 2017-10-06 2019-04-11 Gilead Sciences, Inc. POLYTHERAPY COMPRISING AN ACC INHIBITOR

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
""Safety and pharmacokinetics of DUR-928 in patients with nonalcoholic steatohepatitis - A phase 1b s", JOURNAL OF HEPATOLOGY, vol. 66(1), JPN6025020843, 2017, pages 596, ISSN: 0005603586 *
GASTROENTEROLOGY & HEPATOLOGY, vol. 16(4), JPN6025020844, April 2020 (2020-04-01), pages 178 - 189, ISSN: 0005603587 *
METABOLISM, vol. 71, JPN6025020845, 2017, pages 17 - 32, ISSN: 0005603588 *

Also Published As

Publication number Publication date
WO2021237146A1 (en) 2021-11-25
KR20230015940A (ko) 2023-01-31
AU2021273937A1 (en) 2022-12-15
US20230181602A1 (en) 2023-06-15
BR112022023128A2 (pt) 2022-12-20
MX2022014574A (es) 2022-12-15
CN115803061A (zh) 2023-03-14
TW202210082A (zh) 2022-03-16
EP4153165A1 (en) 2023-03-29
EP4153165A4 (en) 2024-05-01
CA3183119A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
Gawrieh et al. Saroglitazar, a PPAR‐α/γ agonist, for treatment of NAFLD: a randomized controlled double‐blind phase 2 trial
EP3054940B1 (en) Compositions and methods for treating non-alcoholic steatohepatitis
JP6865038B2 (ja) Ｎａｆｌｄおよびｎａｓｈの治療
US10441560B2 (en) Compositions and methods for treating non-alcoholic steatohepatitis
Hari et al. Dyslipidemia and cardiovascular health in childhood nephrotic syndrome
Kargiotis et al. Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report
US20200237696A1 (en) Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis
KR20190044667A (ko) Fxr 작용제의 신규 요법
JP2023526418A (ja) 非アルコール性脂肪性肝炎（ｎａｓｈ）の処置
JP2023527153A (ja) 非アルコール性脂肪性肝炎（ｎａｓｈ）の処置
EP3716975A1 (en) Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis
WO2021237149A2 (en) Treatment of non-alcoholic steatohepatitis (nash)
HK40089720A (zh) 非酒精性脂肪性肝炎(nash)的治疗
HK40089967A (zh) 非酒精性脂肪性肝炎(nash)的治疗
Gil-Extremera et al. Efficacy and safety of ezetimibe/simvastatin co-administered with fenofibrate in mixed hyperlipidemic patients with metabolic syndrome
WO2023210716A1 (ja) Ｃｂｐ／カテニン阻害剤の肝線維症治療レジメン

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230126

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20230126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250527

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250530

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251127